FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281720947> ?p ?o ?g. }

• W4281720947 endingPage "7523" @default.
• W4281720947 startingPage "7523" @default.
• W4281720947 abstract "7523 Background: Outcomes of pts with newly diagnosed DLBCL with high/poor risk according to the revised International Prognostic Index (IPI) treated with immunochemotherapy (IC) remain suboptimal, with a 4-year survival rate of 55% (Sehn et al, Blood 2007). SC epco is a well-tolerated bispecific antibody with single-agent activity in the relapsed/refractory (R/R) aggressive B-cell NHL setting. The mechanism of action and safety profile of epco are distinct from IC, and epco is well suited for use in combinations and in earlier lines of therapy. Addition of a novel agent to standard of care IC may overcome the adverse prognosis of high-risk pts. Presented here are updated results of epco + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in previously untreated DLBCL pts with IPI 3–5 (EPCORE NHL-2 arm 1; NCT04663347). Methods: Adults with previously untreated CD20 + DLBCL and IPI ≥3 received SC epco (every week, cycle [C] 1–4; every 3 weeks, C5–6) + R-CHOP for 6 cycles (21 d) followed by single-agent epco every 4 weeks up to 1 y (in cycles of 28 d). To mitigate CRS, epco step-up dosing and corticosteroid prophylaxis were required. Response was assessed by PET-CT with contrast per Lugano 2014 criteria. Results: As of Dec 1, 2021, 33 pts (median age, 66 y; range, 19–82) received epco + R-CHOP (epco 24 mg, n = 4; 48 mg, n = 29). Median time from diagnosis to first dose was 25 d (range, 5–70). All pts had IPI ≥3 and ≥24% had double- or triple-hit DLBCL. Median follow-up was 3 mo (range, 0–9.7); median number of total cycles initiated was 5 (1–13). Overall, 94% of pts (31/33) remained on Tx. Tx-emergent adverse events (TEAEs) in ≥30% of pts were neutropenia (48%; febrile neutropenia in 9% of all pts), CRS (45%), infections (42%), anemia (39%), injection-site reactions (36%), nausea (33%), constipation (30%), and pyrexia (30%). No TEAEs led to epco discontinuation. AEs of special interest included CRS (42% grade [G] 1/2, 3% G3) and ICANS (3% G2); 1 pt had tumor lysis syndrome (3% G3). Most CRS events occurred in C1 and resolved after a median of 2 days (1–11); 4 pts with CRS received tocilizumab. No fatal TEAEs were reported. In efficacy-evaluable pts, the overall response rate (ORR) was 96% (24/25); 68% (17/25) had complete metabolic response (CMR). For the 10 pts who received 6 cycles of R-CHOP and had a subsequent response assessment, the ORR and CMR rate were 100% and 90%, respectively. As of the data cutoff, all of these 10 pts remained in response, with the longest duration of response 7.1+ mo and ongoing. Updated data will be presented. Conclusions: Epco is the first SC bispecific antibody assessed in combination with standard of care in previously untreated DLBCL. The safety profile of epco + R-CHOP is manageable. CRS events were mostly of low grade and did not lead to Tx discontinuation. ORR and CMR rate were high with no relapses as of the data cutoff date. Clinical trial information: NCT04663347." @default.
• W4281720947 created "2022-06-13" @default.
• W4281720947 creator A5007011861 @default.
• W4281720947 creator A5015988282 @default.
• W4281720947 creator A5017559600 @default.
• W4281720947 creator A5043944883 @default.
• W4281720947 creator A5055723755 @default.
• W4281720947 creator A5064830159 @default.
• W4281720947 creator A5073151572 @default.
• W4281720947 creator A5077730260 @default.
• W4281720947 creator A5081549594 @default.
• W4281720947 creator A5082232325 @default.
• W4281720947 creator A5086774598 @default.
• W4281720947 creator A5089391475 @default.
• W4281720947 creator A5090759974 @default.
• W4281720947 date "2022-06-01" @default.
• W4281720947 modified "2023-10-13" @default.
• W4281720947 title "First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update." @default.
• W4281720947 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.7523" @default.
• W4281720947 hasPublicationYear "2022" @default.
• W4281720947 type Work @default.
• W4281720947 citedByCount "6" @default.
• W4281720947 countsByYear W42817209472022 @default.
• W4281720947 countsByYear W42817209472023 @default.
• W4281720947 crossrefType "journal-article" @default.
• W4281720947 hasAuthorship W4281720947A5007011861 @default.
• W4281720947 hasAuthorship W4281720947A5015988282 @default.
• W4281720947 hasAuthorship W4281720947A5017559600 @default.
• W4281720947 hasAuthorship W4281720947A5043944883 @default.
• W4281720947 hasAuthorship W4281720947A5055723755 @default.
• W4281720947 hasAuthorship W4281720947A5064830159 @default.
• W4281720947 hasAuthorship W4281720947A5073151572 @default.
• W4281720947 hasAuthorship W4281720947A5077730260 @default.
• W4281720947 hasAuthorship W4281720947A5081549594 @default.
• W4281720947 hasAuthorship W4281720947A5082232325 @default.
• W4281720947 hasAuthorship W4281720947A5086774598 @default.
• W4281720947 hasAuthorship W4281720947A5089391475 @default.
• W4281720947 hasAuthorship W4281720947A5090759974 @default.
• W4281720947 hasConcept C126322002 @default.
• W4281720947 hasConcept C143998085 @default.
• W4281720947 hasConcept C2776063141 @default.
• W4281720947 hasConcept C2776364478 @default.
• W4281720947 hasConcept C2776694085 @default.
• W4281720947 hasConcept C2776755627 @default.
• W4281720947 hasConcept C2778559949 @default.
• W4281720947 hasConcept C2778720950 @default.
• W4281720947 hasConcept C2779338263 @default.
• W4281720947 hasConcept C2779429289 @default.
• W4281720947 hasConcept C2780653079 @default.
• W4281720947 hasConcept C71924100 @default.
• W4281720947 hasConceptScore W4281720947C126322002 @default.
• W4281720947 hasConceptScore W4281720947C143998085 @default.
• W4281720947 hasConceptScore W4281720947C2776063141 @default.
• W4281720947 hasConceptScore W4281720947C2776364478 @default.
• W4281720947 hasConceptScore W4281720947C2776694085 @default.
• W4281720947 hasConceptScore W4281720947C2776755627 @default.
• W4281720947 hasConceptScore W4281720947C2778559949 @default.
• W4281720947 hasConceptScore W4281720947C2778720950 @default.
• W4281720947 hasConceptScore W4281720947C2779338263 @default.
• W4281720947 hasConceptScore W4281720947C2779429289 @default.
• W4281720947 hasConceptScore W4281720947C2780653079 @default.
• W4281720947 hasConceptScore W4281720947C71924100 @default.
• W4281720947 hasIssue "16_suppl" @default.
• W4281720947 hasLocation W42817209471 @default.
• W4281720947 hasOpenAccess W4281720947 @default.
• W4281720947 hasPrimaryLocation W42817209471 @default.
• W4281720947 hasRelatedWork W1896861650 @default.
• W4281720947 hasRelatedWork W1921119956 @default.
• W4281720947 hasRelatedWork W1986487042 @default.
• W4281720947 hasRelatedWork W1996462672 @default.
• W4281720947 hasRelatedWork W2017046780 @default.
• W4281720947 hasRelatedWork W2031021461 @default.
• W4281720947 hasRelatedWork W2044362603 @default.
• W4281720947 hasRelatedWork W2047206303 @default.
• W4281720947 hasRelatedWork W2138201596 @default.
• W4281720947 hasRelatedWork W2143831053 @default.
• W4281720947 hasVolume "40" @default.
• W4281720947 isParatext "false" @default.
• W4281720947 isRetracted "false" @default.
• W4281720947 workType "article" @default.